Baxter International Inc
BAX: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| P^c | LOCK|!M&?S | LOCK|X$ |
Baxter's Moat Still Narrow, Despite Recent Bad Capital Allocation Decisions
Business Strategy and Outlook
Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising and supply chain pressures easing, we suspect Baxter's financial prospects will improve, especially in 2025 and beyond, as Baxter renegotiates significant contracts with group purchasing organizations.
